שיחה:מניעה וטיפול בטרשת העורקים ובמחלות כלי דם - הנחיה קלינית

References . 1 Bitzur R, Harats D, Rubinstein A. Guidelines for the prevention and treatment of atherosclerosis and cardiovasculer diseases: treatment of diabetes mellitus, dyslipidemia and the prevention of stroke. Harefuah 2005 144 647-654, 675.

.2        Bitzur R, Harats D, Rubinstein A. Guidelines for the prevention and treatment of

atherosclerosis and cardiovasculer diseases: general recommendations--hypertension. Harefuah 2005 144 506-512, 525. .3 Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24 987-1003. .4 Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 1837-1847. .5 Lichtenstein AH, Appel LJ, Brands M, Carnethon M ,Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006 114 82-96. .6 Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006 113 898-918. .7 Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008 359 229-241. .8 Sofi F, Cesari F, Abbate R, Gensini GF & Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008 337 a1344. .9 Lavie CJ, Milani RV, Mehra MR,Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009 54 585-594. . 10 Kahn EB, Ramsey LT, Brownson RC, Heath GW, Howze EH, Powell KE, et al. The effectiveness of interventions to increase physical activity. A systematic review. Am J Prev Med 2002 22 73-107. . 11 Katzmarzyk PT,Craig CL. Musculoskeletal fitness and risk of mortality. Med Sci Sports Exerc 2002 34 740-744. . 12 Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007 116 1081-1093. 13. Jiang J., Liu B., Sitas F., Zeng X., Chen J., Han W., et al. Tobacco Control. 2009 Sep10[Epub ahead of print] 14. Schroeder SA. What to do with a patient who smokes. JAMA 2005; 294:482 - 487 15. Stead LF, Lancester T. Individual behavioral counseling for smoking cessation. Cochrane Database Syst Rev 2005;18:CD001292. 16. Stead LF, Lancester T. Group interventions for smoking cessation. Cochrane Database Syst Rev 2005; 18:CD001007. 17. Stead LF. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Systemic Rreviews. 2008; CD000146. 18. Hurt R. D. et al. A comparison of sustained release Bupropion and placebo for smoking cessation. New Engl J Med. 1997; 337: 1195 - 1202. 19. Cantrell MA, Geraets D. Varenicline for tobacco dependence. New Engl J Med 2009; 360: 730-731. 20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 289 2560-2572. 21. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 359 2417-2428. 22. Sacks FM, Svetkey LP, Vollmer WM ,Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001 344 3-10. 23. Lasagna L. Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2000 283 2013-2014. 24. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008 358.1887-1898 25. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 229-234. 26. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 317 703-713. 27. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004.685-696 364 28. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 7-22. 29. Standards of medical care in diabetes--2009. Diabetes Care 2009 32 Suppl 1 S13-61. 30. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 28 88-136. 31. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007 28 2375-2414. 32. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 837-853. 33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 1577-1589. 34. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 360 129-139. 35. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 2545-2559. 36. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 2560-2572. 37. Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus Arch Intern Med 2009 169 616-625. 38. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 193-203. 39. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 290 486-494. 40. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet 2009 373 2088-2090. 41. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 2457-2471. 42. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 200.1189-1195 298 7 43. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008 155 712-717. 44. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 358 580-591. 45. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005 46 1405-1410. 46. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009 54 558¬565. 47. Gaspardone A, Arca M. Atorvastatin: its clinical role in cerebrovascular prevention. Drugs 2007 67 Suppl 1 55-62. 48. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97 (suppl): 89c- 94c. 49. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 1267-1278. 50. Clofibrate and niacin in coronary heart disease. JAMA 1975.360-381 231 51. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 345 1583-1592. 52. Fruchart JC, Brewer HB, Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998 81 912-917. 53. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 341 410-418. 54. Viljoen A, Wierzbicki AS. Potential options to treat hypertrigyceridemia. Curr Drug Targets. 2009 10: 356-301 55. Goldberg IJ. Hypertriglyceridemia; impact and treatment. Endocrinol Metabol Clin North Am 2009; 38:137-49. 56. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009 360 1851-1861. 57. Pearson TA, Mensah GA, Alexander RW, Anderson Jl, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. Circualtion 2003; 107: 499-511 58. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 113 2363-2372. 59. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the US Preventive Services task Force. Ann Intern Med 2009;150: 4-5-410 60. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. Management of Patients With Unstable Angina/Non_ST-Elevation Myocardial on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the of the American College of Cardiology/American Heart Association Task Force Angina/Non-ST-Elevation Myocardial Infarction: Executive Summary: A Report ACC/AHA 2007 Guidelines for the Management of Patients With Unstable. Circulation 2007 116: e148-304. 61. Streifler JY, Leker R, Tanne D, Gross B, Lampl Y, Bornstein NM. Guidelines for the management of stroke--2008 invasive measures for prevention of ischemic stroke. Harefuah 2008 147 560-564, 572. 62. Streifler JY, Tanne D, Gross B, Lampl Y, Bornstein NM. Guidelines for the management of stroke--2007 prevention of ischemic stroke--general approach and medical treatment. Harefuah 2007 146 373-379, 405. 63. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002 33 1934-1942. 64. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998 339 1415-1425. 65. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE ,Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003 349 1019-1026. 66. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752. 67. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabe